Loading...
Printed on 6/29/2026
For informational purposes only. This is not medical advice.
Adjusted Body Weight (ABW) is used for drug dosing in obese patients (typically defined as actual body weight > 130% of ideal body weight). Many drugs distribute partially into adipose tissue, so using actual weight leads to overdosing while using ideal weight leads to underdosing. ABW uses a correction factor of 0.4 to estimate effective dosing weight: ABW = IBW + 0.4 × (Actual − IBW). This is commonly used for aminoglycoside dosing, vancomycin loading doses, and some chemotherapy regimens. Calculate IBW baseline with [Ideal Weight Calculator](/tools/ideal-weight). For aminoglycoside dosing using ABW, use [Gentamicin Dosing Calculator](/tools/gentamicin-dosing). For vancomycin loading, refer to [Vancomycin Dosing Calculator](/tools/vancomycin-dosing). Monitor renal function to adjust doses with [eGFR Calculator](/tools/egfr-calculator) and [Creatinine Clearance](/tools/creatinine-clearance).
Formula: ABW = IBW + 0.4 × (Actual Weight − IBW)
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
IBW is calculated using the Devine formula: Men: IBW = 50 + 2.3 × (height in inches - 60); Women: IBW = 45.5 + 2.3 × (height in inches - 60). IBW reflects the weight associated with minimal cardiovascular and metabolic risk, and approximates lean body mass for pharmacokinetic purposes. IBW alone is used for tidal volume calculation in ARDS (6 mL/kg IBW).
Adjusted body weight is used when actual body weight (ABW) exceeds IBW by more than 20-30% (typically when ABW is greater than 130% of IBW). Below this threshold, either IBW or actual weight is appropriate depending on the drug. ABW is not needed when actual weight is at or below IBW.
Adjusted Body Weight = IBW + 0.4 × (Actual Weight - IBW). The 0.4 factor reflects approximately 40% drug distribution into excess adipose tissue compared to lean tissue. Example: IBW 70 kg, actual weight 120 kg — ABW = 70 + 0.4 × (120 - 70) = 70 + 20 = 90 kg. Use this value for aminoglycoside dosing, and consult drug-specific guidelines for other medications.
Pharmacists, infectious disease physicians
Aminoglycosides (gentamicin, tobramycin, amikacin) are the canonical drugs for ABW dosing. Studies by Bauer et al. (1983) demonstrated that aminoglycosides distribute approximately 40% into excess adipose tissue. Using actual weight causes overdosing and nephrotoxicity; using IBW causes underdosing and treatment failure. ABW = IBW + 0.4 × (Actual - IBW) produces accurate pharmacokinetics. Therapeutic drug monitoring (peak and trough levels) should guide subsequent dosing.
Intensivists, respiratory therapists
In ARDS, protective lung ventilation (ARDSnet protocol) mandates tidal volume of 6 mL/kg IBW — NOT ABW or actual weight. Lung size correlates with height and sex, not obesity. An obese patient at 150 kg with IBW of 70 kg should receive 6 mL/kg × 70 kg = 420 mL tidal volume. Using actual weight (900 mL) causes volutrauma and dramatically increases ARDS mortality. This is the most critical weight-based calculation error to avoid.
Pharmacists, infectious disease physicians
Per 2020 ASHP/IDSA/SIDP Vancomycin Guidelines, total daily dose of vancomycin uses actual body weight (not ABW) in obese patients, because vancomycin volume of distribution increases proportionally with weight. However, the goal is achieving target AUC/MIC rather than a specific mg/kg dose. Therapeutic drug monitoring (vancomycin AUC via Bayesian pharmacokinetic methods) is now the recommended monitoring approach in obese patients.
Hospitalists, hematologists, surgeons
Enoxaparin for DVT treatment: use actual body weight up to 144 kg (weight-capped at 144 kg per most guidelines). For morbidly obese patients (above 144 kg or BMI above 40), anti-Xa monitoring is recommended to verify therapeutic levels. DVT prophylaxis: standard dose (40 mg daily) may be insufficient — some institutions use 40 mg twice daily or weight-based prophylaxis with anti-Xa monitoring for morbidly obese patients.
Oncologists, pharmacists
ASCO guidelines (2012) recommend using actual body weight for chemotherapy dose calculation in obese patients, even when this results in doses that may seem high. Capping or reducing doses based on weight leads to under-treatment and worse cancer outcomes. Most cytotoxic chemotherapy distributes based on actual body mass. Some regimens specify BSA (body surface area) using actual weight, or have protocol-specific maximum dose caps.
The 0.4 correction factor comes from aminoglycoside pharmacokinetic studies in obese patients (Bauer et al., 1983). It reflects 40% distribution of aminoglycosides into adipose tissue relative to lean tissue. This factor may not apply to other drug classes — check drug-specific literature before assuming 0.4 is correct for a given medication.
Despite common misconceptions, the 2020 ASHP/IDSA/SIDP Vancomycin Consensus Guidelines recommend using actual body weight for total daily dose calculation (not ABW). The goal has shifted from mg/kg dosing to AUC/MIC targeting (AUC 400-600 mg/h/L for MRSA) using Bayesian pharmacokinetic tools. Pharmacist consultation and TDM are essential in obese patients.
This is arguably the most clinically critical weight-based dosing principle. The ARDSnet protocol (NEJM 2000) proved 6 mL/kg IBW tidal volume reduces ARDS mortality by 22% compared to 12 mL/kg. In a 150 kg patient with IBW of 70 kg, the target tidal volume is 420 mL (6 × 70), not 900 mL (6 × 150). Using actual weight in ARDS ventilation can be lethal.
Drugs with very high volumes of distribution that distribute extensively into adipose tissue often follow actual body weight: azithromycin, fluoroquinolones (ciprofloxacin, levofloxacin), metronidazole, doxycycline. For these agents, IBW or ABW may result in underdosing. Always verify by drug class.
For calculating creatinine clearance (CrCl) for renal dosing using the Cockcroft-Gault equation in obese patients, use the lesser of IBW or actual body weight unless the patient is malnourished. Some guidelines recommend using ABW for CrCl if the drug is renally cleared with a narrow therapeutic index. Using actual weight in the Cockcroft-Gault equation can overestimate CrCl and result in drug toxicity.
Body surface area (BSA) for chemotherapy is calculated using actual height and actual weight (Mosteller formula: BSA = sqrt(height cm × weight kg / 3600)). ASCO 2012 guidelines support full weight-based dosing in obese cancer patients. Protocol-specific dose caps should be applied per the specific regimen — these vary widely by drug and study.
ABW calculations assume relatively stable body composition. In critically ill patients, massive fluid resuscitation can add 10-30 kg of edema weight within hours, completely changing the denominator for weight-based dosing. In septic shock with significant volume overload, discuss with pharmacy whether to use dry (estimated pre-illness) weight or current weight for dosing.
Weight-based dosing formulas, including ABW, provide a starting point. For drugs with narrow therapeutic indices (aminoglycosides, vancomycin), therapeutic drug monitoring (TDM) with serum drug level measurement is essential to verify appropriate dosing in obese patients. Population pharmacokinetic estimates have wide variability — TDM removes this uncertainty.
IBW formulas by Devine (1974). ABW correction factor of 0.4 from aminoglycoside pharmacokinetics in obese patients: Bauer et al. (Am J Hosp Pharm 1983). Tidal volume in ARDS using IBW: The ARDS Network (NEJM 2000). Vancomycin actual body weight dosing per 2020 ASHP/IDSA/SIDP Consensus Guidelines (AJHP 2020). Enoxaparin in morbid obesity: Rondina et al. (Thromb Haemost 2010). ASCO full-dose chemotherapy in obesity: Griggs et al. (J Clin Oncol 2012). Obesity pharmacokinetics review: Hanley et al. (Anesthesiology 2010).
Your adjusted body weight (ABW) represents the recommended dosing weight for medications that distribute partially into adipose tissue. It falls between your ideal body weight (IBW) and your actual body weight, reflecting the fact that most drugs penetrate fat tissue to some degree but not as fully as lean tissue. If the calculator indicates that your actual weight does not exceed 130% of your IBW, adjusted body weight may not be necessary — standard IBW or actual weight-based dosing may be appropriate depending on the drug.
The ABW is calculated using a correction factor of 0.4, which approximates 40% drug distribution into excess adipose tissue. This means 40% of the difference between actual weight and ideal weight is added to the ideal weight. For example, if IBW is 70 kg and actual weight is 120 kg, ABW = 70 + 0.4 × (120 − 70) = 90 kg. This value should be used as a starting point for dosing, with subsequent adjustments based on drug levels, clinical response, and renal function.
Use adjusted body weight for drug dosing when a patient's actual body weight exceeds 130% of their ideal body weight (i.e., the patient is significantly obese) and the drug in question is known to distribute partially into adipose tissue. The most common clinical applications include aminoglycoside antibiotics (gentamicin, tobramycin, amikacin), vancomycin loading doses, and certain chemotherapy regimens.
This calculation is most frequently performed by pharmacists and clinicians in the hospital setting when initiating weight-based drug therapy in obese patients. It is also relevant in the outpatient setting for medications like low molecular weight heparin in some protocols. Always cross-reference with current drug-specific dosing guidelines, as some medications use actual body weight, some use ideal body weight, and some use adjusted body weight with different correction factors.
The 0.4 correction factor is a generalized estimate and may not be accurate for all drugs. Some medications distribute more extensively into adipose tissue (and may require a higher correction factor or actual body weight), while others distribute minimally into fat (and may be best dosed on IBW alone). The correction factor was primarily derived from pharmacokinetic studies of aminoglycosides and may not generalize perfectly to all drug classes.
The underlying ideal body weight calculation (Devine formula) has its own limitations — it was derived from life insurance data in the 1970s and may not perfectly reflect healthy weight across all populations. Additionally, ABW does not account for individual variation in body composition, fluid status, or organ function. In critically ill patients, volume of distribution can change dramatically due to fluid shifts, making any weight-based estimate less reliable. Therapeutic drug monitoring (when available) remains the gold standard for optimizing drug dosing in obese patients.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Calculate ideal body weight (IBW) using Devine, Robinson, Miller, and Hamwi formulas. Find a practical healthy weight range by height and sex.
OpenBody MetricsCalculate body surface area (BSA) with Du Bois, Mosteller, and Haycock formulas for chemotherapy dosing, cardiac index, and clinical calculations.
OpenPharmacyCalculate gentamicin dose and interval using extended-interval (5–7 mg/kg q24h) or traditional q8–12h dosing methods based on creatinine clearance and adjusted body weight.
Open